Stockscreener 앱 받기
28.65
0.77%
0.22
시간 외 거래:
28.65
Lenz Therapeutics Inc 주식(LENZ)의 최신 뉴스
LENZ Therapeutics (LENZ) to Release Earnings on Wednesday - MarketBeat
Registration Open for CME/CE-Accredited Free Event Nov 7 - InvisionMag
LENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024 - The Manila Times
LENZ Therapeutics Insider Buyers See Boost After Market Cap Rose US$97m - Simply Wall St
Corxel and LENZ share positive results from Phase III China trial - The Pharma Letter
LENZ reports positive Chinese study data for far-sightedness drug - MSN
LENZ Therapeutics' Investigational Drug For Age-Related Blindness Aces Pivotal China Trial, Analyst Says Data Readout May Strengthen Position For Ex-U.S. Partnerships - AOL
Wescott Financial Advisory Group LLC Acquires 2,154 Shares of NVIDIA Co. (NASDAQ:NVDA) - Defense World
Pre-market Movers: EVOK, HCTI, GLUE, MNPR... - RTTNews
LENZ Therapeutics Shares Climb After Presbyopia Trial Hits Endpoints - MarketWatch
CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100 - ForexTV.com
CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial - The Bakersfield Californian
VERV DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Verve Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERV - ForexTV.com
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives $35.40 Average Price Target from Analysts - MarketBeat
Lenz Therapeutics announces FDA acceptance of NDA for LNZ100 - Yahoo Finance
Mcf Energy Ltd (MCF-X) QuotePress Release - The Globe and Mail
LENZ Therapeutics Shares Rise After FDA Accepts Application for Potential Eye Condition Treatment - Marketscreener.com
Why LENZ Therapeutics Stock Hit A New 52-Week High Today - Benzinga
One new option listing and ten option delistings on October 21st - TipRanks
LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia - The Manila Times
LENZ Therapeutics, Inc. Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia - Marketscreener.com
Behind the Bell: LENZ Therapeutics - Nasdaq
FY2028 Earnings Estimate for LENZ Issued By Leerink Partnrs - MarketBeat
Presbyopia Market on Track for Major Expansion by 2034, - openPR
Presbyopia Market on Track for Major Expansion by 2034, According to DelveInsight | Eyenovia, Orasis Pharma, Ocuphire Pharma, Novartis, Visus Therapeutics - The Globe and Mail
Preterm Birth and PROM Testing Market Expected to Grow at 8.6% CAGR, projected to Reach USD 562.1 million by 2034 | States Transparency Market Research, Inc. - Yahoo Finance
Lenz Co. stock soars to 52-week high, hits $26.18 By Investing.com - Investing.com Canada
Lucy Therapeutics Appoints Kim Drapkin as Board Chair - BioSpace
Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences - Yahoo Finance
TJX Companies (TJX-N) QuotePress Release - The Globe and Mail
Dimensional Fund Advisors LP Increases Holdings in Koss Co. (NASDAQ:KOSS) - Defense World
Creative Planning Buys 296 Shares of PVH Corp. (NYSE:PVH) - Defense World
ABVC BioPharma, Inc. (NASDAQ:ABVC) Sees Large Increase in Short Interest - Defense World
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Acquired by The Manufacturers Life Insurance Company - MarketBeat
Neumora Therapeutics executive sells over $200k in company stock By Investing.com - Investing.com Australia
Neumora Therapeutics executive sells over $200k in company stock - Investing.com India
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Insider Robert A. Lenz Sells 5,563 Shares - MarketBeat
Neumora Therapeutics Inc. [NMRA] Records 50-Day SMA of $12.22 - Knox Daily
Marshall Wace LLP Invests $390,000 in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat
Market Momentum Report: Neumora Therapeutics Inc. (NMRA)’s Positive Close at 14.74 - The Dwinnex
LENZEyeing A Slice Of The Presbyopia Pie - RTTNews
LENZ stock touches 52-week high at $25.85 amid market optimism - Investing.com Canada
Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases - ForexTV.com
Potential Price Increase for Neumora Therapeutics Inc. (NMRA) After Recent Insider Activity - Knox Daily
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Canada Pension Plan Investment Board Makes New $26,000 Investment in Mesa Laboratories, Inc. (NASDAQ:MLAB) - Defense World
Xponance Inc. Cuts Position in Darling Ingredients Inc. (NYSE:DAR) - Defense World
EURETINA 2024: CRISPR-Cas mediated base editing approaches for CRB1 related retinal dystrophy - Modern Retina
LENZ Therapeutics Announces Presentations at Upcoming Ophthalmology and Optometry Medical Conferences - The Manila Times
Metavesco Acquires Assets From Epic Labor - The Manila Times
Achieve, INmune, Lenz gain on bullish initiations from Raymond James - MSN
Congress Intermediate Bond ETF Announces Dividend of $0.01 (NYSEARCA:CAFX) - Defense World
EURETINA 2024: Ultra widefield OCT and the benefits of improved imaging - Modern Retina
Achieve, INmune, Lenz stocks win bullish view from RayJay - Seeking Alpha
Raymond James bullish on Lenz Therapeutics stock, highlights large presbyopia market - Investing.com
LENZ Therapeutics (NASDAQ:LENZ) Now Covered by Analysts at Raymond James - MarketBeat
EURETINA 2024: The importance of the international retina community - Modern Retina
Neumora Therapeutics Inc. (NMRA) gets rating Initiated from Needham - Knox Daily
Understanding the Risks of Investing in LENZ Therapeutics Inc. (LENZ) - Knox Daily
Bank of New York Mellon Corp Has $746,000 Stock Holdings in Porch Group, Inc. (NASDAQ:PRCH) - Defense World
Bank of New York Mellon Corp Buys 2,771 Shares of BlackRock MuniYield Quality Fund, Inc. (NYSE:MQY) - Defense World
2.02%
0.47%
자본화:
|
볼륨(24시간):